Navigation Links
GeneLink Reports First Quarter Gains
Date:5/11/2010

ORLANDO, Fla., May 11 /PRNewswire-FirstCall/ -- GeneLink, Inc. (OTC Bulletin Board: GNLK), a leading consumer genomics biotech company, today reported financial results for the fiscal quarter ended March 31, 2010.

Financial Highlights:

  • Continued progress towards profitability: Quarterly operating loss reduced by 14% over Q4 2009
  • Comparable quarter gross profit improvement over Q1 2009 of 37%
  • Q1 Revenues of  $2,221,111, a 12.6% increase over Q1 2009

Gary Beeman, GeneLink's CEO stated, "The first quarter of 2010 continues to reflect the positive impact of the steps initiated in late 2009 to increase our profit margins as GeneLink continued to make progress towards profitability in 2010, with operating losses dropping 14% as compared to the prior quarter.  In addition to continuing our investment in growing and improving the financial performance of our existing GeneWize sales operations, we are focusing on expanding the revenue base at GeneLink in market areas that we previously could not reach."  

Dr. Bernard Kasten, GeneLink's Executive Chairman added, "The first quarter was notable not only for the continued reduction of losses, but more so for the addition of Gary Beeman as CEO.  Gary has already helped GeneLink expand its vision and aspirations in ways which will start to evidence themselves in the coming months in our product offerings, business partnerships, and financial performance."

About GeneLink Biosciences, Inc.:

GeneLink is a 16-year old leading biosciences company specializing in consumer genomics. GeneLink's patented and patent pending technologies include proprietary genetic assessments and specific DNA tests linked to personalized health, beauty and wellness applications and products. Its DNA assessments provide information that enables the customization of nutritional products, vitamin and supplement products, specific-condition nutraceuticals, skincare products and health maintenance regimens designed to fulfill individual consumer wellness needs. For more information visit www.genelinkbio.com

This release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GeneLink disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.


'/>"/>
SOURCE GeneLink, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
2. Winner Medical Reports Second Quarter Results for the Fiscal Year 2010
3. China Pharma Holdings, Inc. Reports First Quarter 2010 Financial Results
4. BMP Sunstone Reports First Quarter 2010 Financial Results
5. American Oriental Bioengineering Reports First Quarter 2010 Financial Results
6. OncoGenex Reports First Quarter Financial Results
7. Oncothyreon reports full year and fourth quarter 2009 financial results
8. Oncothyreon reports first quarter 2010 financial results
9. Oramed Pharmaceuticals Reports Results in Phase 2b Trial of Oral Insulin Administration to Type 2 Diabetes Patients
10. Epeius Biotechnologies Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy
11. Anavex reports animal study results as lead Alzheimers compound approaches phase 1 clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... PETACH TIKVAH, Israel , ... Inc. (NASDAQ: BCLI), a leading developer of ... announced financial results for the year ended ... a highly successful and pivotal year for Brainstorm, with ... progress made on clinical, regulatory and operational fronts," ...
(Date:3/29/2017)... LINCOLN, Mass. , March 29, 2017 ... industry-leader in applying mechanistic modeling to drug ... of their collaboration with Zymeworks Inc. for ... drug conjugate therapeutics intended for the treatment ... has supported Zymeworks previously for GLP toxicology ...
(Date:3/29/2017)... ... March 29, 2017 , ... ACEA ... assays, disperses a quarterly travel award to noteworthy scientists who will be presenting ... that its new round of awards are being given to two postdoctoral fellows ...
(Date:3/29/2017)... Research and Markets has announced the addition of the "Global ... report to their offering. ... The Global Agricultural Chelates Market is poised to ... to reach approximately $825.4 million by 2025. This ... given segments on global as well as regional levels presented in ...
Breaking Biology Technology:
(Date:3/22/2017)... Vigilant Solutions , a vehicle location ... announced today the appointment of retired FBI special agent ... business development. Mr. Sheridan brings more than ... focus on the aviation transportation sector, to his new ... Sheridan served as the Aviation Liaison Agent Coordinator (ALAC) ...
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in Germany ... ... one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial contribution ... ...
(Date:3/9/2017)... and MOUNTAIN VIEW, Calif. ... "Eating Well Made Simple," and 23andMe , the ... guide better food choices.  Zipongo can now provide customers ... food preferences, health goals and biometrics, but also genetic ... food choices. Zipongo,s personalized food decision support ...
Breaking Biology News(10 mins):